Tackling the malaria pathogen P. falciparum has been complex, due to rapid development of resistance. A new compound targets liver stages of the parasite and, thus, provides a new mode of action to reduce the population of the parasite.
Together with the EIB, five of the EU’s largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_2017_Winter_landfil.png5631000Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-19 05:58:002019-07-19 05:58:00Billions for the circular economy
The European Biotechnology Science & Industry Guide provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry, and is now also available as part of the BIOCOM app!
https://european-biotechnology.com/wp-content/uploads/2024/04/Guide-2019-EU_App-Now_800x450.jpg450800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-07-17 15:09:252024-04-02 15:51:36European Biotechnology Guide now available on app!
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-17 09:58:002019-07-17 09:58:00AM-Pharma raises €116m for Phase III
Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform.
It’s no easy task to develop medications that are effective and safe to use. The pharmaceutical industry loses billions every year due to safety-related attrition during the drug discovery process. For both patients and companies, improving productivity in the area would bring significant benefits. Now novel biomarkers designed to better detect and manage drug-induced organ injury – both preclinically and clinically – could make the process faster, safer and cheaper. tg
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Summer_2019_Pancreaticorganoid.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-07-15 14:05:162024-04-02 16:20:43Making every cent in testing count
https://european-biotechnology.com/wp-content/uploads/2024/04/20190715-compound-library.jpg5741020Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-15 10:58:002019-07-15 10:58:00Boehringer snaps up cancer vaccine developer
Healx, a Cambridge, UK, technology company developing treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-07-11 13:54:002019-07-11 13:54:00Neil Thompson appointed CSO of Healx
Controlled human malaria infection trials
BackgroundTackling the malaria pathogen P. falciparum has been complex, due to rapid development of resistance. A new compound targets liver stages of the parasite and, thus, provides a new mode of action to reduce the population of the parasite.
Billions for the circular economy
Latest NewsTogether with the EIB, five of the EU’s largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy.
Genmab launches US$502m IPO
Latest NewsDanish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.
European Biotechnology Guide now available on app!
ProductsThe European Biotechnology Science & Industry Guide provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry, and is now also available as part of the BIOCOM app!
AM-Pharma raises €116m for Phase III
Latest NewsDutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III.
US$5bn deal for Galapagos
Latest NewsBelgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform.
Making every cent in testing count
BackgroundIt’s no easy task to develop medications that are effective and safe to use. The pharmaceutical industry loses billions every year due to safety-related attrition during the drug discovery process. For both patients and companies, improving productivity in the area would bring significant benefits. Now novel biomarkers designed to better detect and manage drug-induced organ injury – both preclinically and clinically – could make the process faster, safer and cheaper. tg
Boehringer snaps up cancer vaccine developer
Latest NewsGerman pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
€28.5m for microalgae expert Microphyt
Latest NewsFrench microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics.
Neil Thompson appointed CSO of Healx
AppointmentsHealx, a Cambridge, UK, technology company developing treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).